Sign up
Pharma Capital

UBS downgrades Smith & Nephew on surgical robot market concerns

UBS also sees a potential slowdown in Smith & Nephew's hip and knee market
Smith & Nephew CEO Namal Nawana
Smith & Nephew's new CEO needs to unveil an updated strategy, says UBS

Swiss bank UBS has downgraded its recommendation on Smith & Nephew PLC’s (LON:SN.) shares to ‘neutral’ from ‘buy’ due to scepticism over the share of the surgical robots market the medical equipment manufacturer will be able to command.

UBS also cut Smith & Nephew’s price target to 1,340p from 1,363p.

READ: New Smith & Nephew boss gives bullish assessment of artificial hip maker’s health

“Our underlying market view is that the adoption of surgical robots will be widespread in orthopaedics has not changed. However, we now believe our initial assumption of S&N’s share of the market was too positive,” UBS analysts said.

The bank also said it sees a risk of a potential slowdown in the hip and knee market and could not be more positive on the company’s prospects until new CEO Namal Nawana unveils a "concrete strategy" for the group.

Shares in Smith & Nephew pared early losses and were trading down 0.3% at 1,359p in mid-morning trade.



Register here to be notified of future SN. Company articles
View full SN. profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.